News and Trends 12 Sep 2016
Celyad’s unique CAR-T approach is ready for Efficacy Studies
The Belgian company has completed a successful Phase I trial for its NKR-2 T-cell therapy in patients with Leukemia and Myeloma,…
Celyad
- Latest Posts
News and Trends 6 Jul 2016
June was a Tough Month for European Biotech… #Fail
Abivax, Celyad, Circassia and Genticel - these are all European Biotechs that took a hit after failing key clinical trials…
News and Trends 29 Jun 2016
Cell Therapy for Heart Failure fails in Phase III … but not Entirely
Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have…
News and Trends 23 Feb 2016
7 Trendy European Biotechs Listed on the NASDAQ in 2016
Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and…
ADVERTISEMENT
News and Trends 6 Nov 2015
Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?
About 30%. That's how Cellectis' NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically,…
News and Trends 29 Oct 2015
ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells
ERRATUM: I published a first article on Celyad's new patent on last Tuesday where I made an error of judgement.…
News and Trends 15 Sep 2015
Louvain-la-Neuve: A Belgian temple for success in cell therapy
Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully…
News and Trends 28 May 2015
Biotechs outperformed in the top 40 European Tech Companies
EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch…
News and Trends 1 Apr 2015
Cardio3 will launch an IPO in the United States
Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today…